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Abstract
Background: The use of herbal medicines for health prevention and ailments is an increasing trend worldwide.
Women in pregnancy are no exception; the reported prevalence of herbal medicine use in pregnancy ranges from
1 to 60 %. Despite a common perception of safety, herbal medicines may have potent pharmacological actions,
and historically, have been used for this reason.
Methods: A multinational, cross-sectional study on how women treat disease and pregnancy-related health ailments
was conducted between October 2011 and February 2012 in Europe, North America, and Australia. This study’s primary
aim was to evaluate and classify the herbal medicines used according to their safety in pregnancy and, secondly, to
investigate risk factors associated with the use of contraindicated herbal medicines during pregnancy.
Results: In total, 29.3 % of the women (n = 2673) reported the use of herbal medicines in pregnancy; of which we were
able to identify 126 specific herbal medicines used by 2379 women (89.0 %). Twenty seven out of 126 herbal medicines
were classified as contraindicated in pregnancy, and were used by 476 women (20.0 %). Twenty-eight were classified
as safe for use in pregnancy and used by the largest number of women (n = 1128, 47.4 %). The greatest number
was classified as requiring caution in pregnancy; these sixty herbal medicines were used by 751 women (31.6 %).
Maternal factors associated with the use of contraindicated herbal medicines in pregnancy were found to be
working in the home, having a university education, not using folic acid, and consuming alcohol. Interestingly, the
recommendation to take a contraindicated herbal medicine was three times more likely to be from a healthcare
practitioner (HCP) than an informal source.
Conclusion: Based on the current literature the majority of women in this study used an herbal medicine that was
classified as safe for use in pregnancy. Women who reported taking a contraindicated herb were more likely to have
been recommended it use by an HCP rather than informal source(s), indicating an urgent need for more education
among HCPs. The paucity of human studies on herbal medicines safety in pregnancy stands in stark contrast to the
widespread use of these products among pregnant women.
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Background
The use of herbal medicines for health prevention and
ailments is an increasing trend worldwide. A recent re-
port on international herbal sales suggests that by 2015
sales are expected to reach $93 billion dollars, up from
$33 billion in 2010 [1]. Women in pregnancy are no ex-
ception; a review of studies from the Western world, re-
ported that the prevalence of herbal medicine use in
pregnancy ranged from 1 to 60 % [2]. The prevalence
rates were 34 % in Australia [3], 58 % in the United
Kingdom [4], 40 % in Norway [5], 48 % in Italy [6] and
6–9 % in the US and Canada [7, 8]. In pregnancy,
women often use herbal medicines due to the perception
that these substances are more natural and therefore
safer to use as compared to pharmaceutical medicines
[2, 9–11]. Research suggests that in many instances, the
use of herbal medicines speaks to a woman’s wish to
have greater choice in their health and aligns with their
desire for a holistic approach to their well-being [2, 12].
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In most countries, herbal medicines are available as
non-prescription medicines. Given such ease of access,
most women report that the decision to use an herbal
medicine came from either their own initiative or on the
recommendation from family and/or friends. A small per-
centage of women do report that the recommendation to
use an herbal medicine came from a healthcare practi-
tioner (HCP) [2, 13, 14]. One study evaluated 400 different
women’s knowledge regarding the indications for use of
10 specific herbal medicines (bearberry, dandelion, echin-
acea, ginkgo, hops, horsetail, lemon balm, St. John’s
wort, sage, and valerian). These researchers found that
over 78.3 % of the women surveyed had little know-
ledge regarding the indications for use of these herbal
medicines, even though 31.3 % had used the herbal
medicine in their pregnancy [10].
Despite this common perception of safety, herbal med-
icines may have potent pharmacological actions, and
have, in fact, been used for centuries, for example as em-
menagogues to promote abortion. Moreover, very little
is known about the extent to which potentially harmful
herbal medicines are used in pregnancy. Concerns range,
with some herbal medicines, from teratogenicity to an
increased risk of maternal bleeding or impact on neo-
natal hormones due to the hormonal nature of the herbal
medicine [15]. In a previous study, 39 % of the women
reporting having used herbal medicines during pregnancy
had used herbal medicines that were considered possibly
harmful or herbs where information about safety in preg-
nancy was missing [16].
This article is a continuation of the investigations of our
previously published study on the use of herbal medicines
in pregnancy among more than 9000 women across 18
countries and five regions of the world. More than one out
of four women (28.9 %) reported using 127 different herbal
medicines during pregnancy [13]. The objective of the
present study is to evaluate and classify these herbal medi-
cines according to their safety in pregnancy based on
current literature and determine the proportion of women
using herbals in each of the safety categories. A second
objective was to investigate risk factors associated with the
use of potentially hazardous herbal medicines during
pregnancy.
Methods
Study data and population
This was a multinational, cross-sectional study con-
ducted in 18 countries (Australia, Austria, Canada, Croatia,
Finland, France, Iceland, Italy, Norway, Poland, Russia,
Serbia, Slovenia, Sweden, Switzerland, The Netherlands,
United Kingdom, and USA) between October 1st 2011 and
February 29th 2012. Women were eligible to participate if
they were pregnant or had at least one child less than 1 year
of age. Women were recruited to complete an online-self-
reported questionnaire via the placement of banners (invi-
tation to participate in the study) on national websites and/
or social networks frequently visited by pregnant women
and new mothers. The banners contained information
about the rationale behind the study and the criteria for
partcipation such as: “Moms-to-be and new moms, share
your thoughts in an international survey about your views
on medication use in pregnancy. Click here to read
more about the study and take part.” In each participat-
ing country, the online questionnaire was available for
2 months. The survey questionnaire was administered
by Questback (http://www.questback.com). A detailed
description of the study design and methods has been
published previously [13].
Consent was obtained from each participant. When a
woman clicked on the survey link, a description of the
study was presented and she was asked whether she was
willing to participate. Informed consent was given by
ticking a Yes response. The Regional Ethic Committee,
Region South-East in Norway, evaluated the study proto-
col in its multinational aspect and approved the study.
Further approvals were provided from the Faculty of
Medicine and Health Science Research Ethics Commit-
tee of the University of East Anglia in the UK, The Na-
tional Bioethics Committee in Iceland and The Scientific
Ethic Board, and Provincial Health Service of Trento in
Italy. Permission to analyze the herbal medicine study
data was also obtained from the Research Ethic Board of
the Hospital for Sick Children, Toronto, Canada. All
data were handled and stored anonymously.
The online questionnaire captured data on maternal
health, socio-demographic, and lifestyle characteristics as
well as use of herbal and conventional medicines in preg-
nancy. Maternal characteristics included age, marital sta-
tus, educational level, mother tongue, employment status,
parity, pregnancy intention, and information on use of
assisted reproductive technology. Life-style characteristics
included folic acid use and smoking status before and dur-
ing pregnancy and alcohol consumption after awareness
of pregnancy.
The following question about use of herbal medicine was
posed to all study participants “Did you take any herbal
preparations during pregnancy (e.g. ginger, echinacea, valer-
ian, cranberries)? If yes, please provide the name of all
herbal preparations you have taken during pregnancy”.
Herbal medicine use could also be reported under the spe-
cific questions about diseases and pregnancy-related health
ailments throughout the questionnaire, as described in de-
tail elsewhere [13]. The names of all herbal medicines used
during pregnancy were captured as free text. Herbal medi-
cine were defined according to the World Health Organiza-
tion’s definition: “any medicinal product based on herbs,
herbal materials, herbal preparations and finished herbal
products, that contain as active ingredients parts of plants,
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other plant materials, or combinations thereof ” [17]. Medi-
cinal products based on animal components, vitamins,
minerals or homeopathic products were not considered
herbal medicines.
A pre-determined herbal medicine classification list
(common name and Latin name) was compiled by the
study team and followed the format of the World Health
Organization’s Anatomical Therapeutic Chemical (ATC)
code convention as a means to standardize the coding in
the questionnaire database. The free text responses were
coded according to this pre-determined classification list
by the national coordinator in each country. When a prod-
uct name representing a multi-herbal combination or com-
bination product was entered, an internet search on the
product name was performed and the botanical ingredi-
ent(s) coded according to the pre-determined classifica-
tion list. Any mineral supplement(s) and vitamins were
recorded separately whenever present in the combination
product and excluded from the estimation of herbal use.
The form of the herbal medicine (tea, tablet, or tincture)
was not specifically requested nor was the dose.
In the survey, women were asked to identify the source(s)
of the recommendation to use the herbal medicine. The
reported sources were then categorized into the following
groups: informal (including the sources: own initiative,
family/friends, internet, magazines/media and herbal
shop personnel), healthcare provider (including the sources:
physician, midwife/nurse and pharmacy personnel), and
other (neither informal nor HCP). Women who had re-
sponses from both informal and HCP recommendation
sources were classified into the “Both informal and HCP
group”.
Determination of the safety classification of herbal
medicines
Herbal medicines were categorized into one of four
safety categories; safe, caution, contraindicated or un-
known (Table 1) based on a summary of the literature,
reference textbooks and monographs. The safety classi-
fications were defined as shown in Table 1.
The safety classification was determined by recording
the current classification of each herbal medicine from the
available reference sources. Several reference sources were
reviewed in order to capture different perspectives when
classifying the individual herbal medicines: The Australian
text book “The Essential Guide to Herbal Safety” [18] The
European Medicines Agency’s [19] and North America
(Herbal Medicines in Pregnancy & Lactation [15], Botan-
ical Safety Handbook [20], and Botanical Medicine for
Women’s Health [21], and Natural Medicines database
[22]). If a particular herbal medicine was not listed in the
above mentioned reference sources, additional sources
were used; Handbook of Medicinal Herbs [23] and PDR
for Herbal Medicines [24]. The Handbook of Medicinal
Herbs identifies contraindications from multiple sources,
often an earlier edition of the Botanical Safety Handbook.
For those herbal medicines which were not listed in any
of the referenced books mentioned above, searches in
Pubmed, and EBSCO (Alt HealthWatch, AMED, Biomed-
ical Reference Collection, Psychology and Behavioral
Sciences Collection, CINHAL Plus, MEDLINE) were per-
formed using first the combination of the terms: “herbal
common name and pregnancy” then the “Latin name and
pregnancy”. In addition, we performed a search of NCBI’s
PubMed database for each of the 125 individual herbal
medications reported in the study to identify whether
there was evidence of safety in pregnancy. Evidence from
controlled studies in human pregnancy was considered
first. If no evidence in human studies was available, then
in vivo research was considered in the classification. The
searches were performed from inception to July 2015.
Once the safety classification of each herbal medicine
was compiled from the different sources, one author
(DAK) reviewed the information and assigned the pre-
liminary classification. The safety classification for each
herbal medicine was reviewed by the co-authors (DAK,
HN, and Gro Cecilie Havnen) and all discrepancies dis-
cussed until agreement was obtained.
We made two assumptions to the safety classifications;
1) that the classification is for the herbal medicine itself
Table 1 Overview of herbal medicines used in pregnancy according to safety classification and number of users
Classification Description Number of herbs (%) Number of users (%)
Total: 126 (100.0) 4,911 (100.00)
Safe Evidence for the safety of the herb in pregnancy. 28 (22.2) 2,347 (47.8)
Caution Caution regarding this herb in pregnancy because there is either no or
limited human evidence or results suggest that this herb should be
used under the supervision of a qualified health care practitioner.
60 (47.6) 1,902 (38.7)
Contraindicated The use of the herb in pregnancy has demonstrated negative impacts
on the pregnancy or fetus.
27 (21.4) 609 (12.4)
Unknown No reference regarding the use of this herb in pregnancy was found. 11 (8.7) 55 (1.1)
It is important to note that being classified in the “caution” category, does not necessarily imply that the herbal medicine should not be used in pregnancy.
Rather it is an indication that either the herbal medicine should be for a specific time period in the pregnancy or under the supervision of a qualified
healthcare practitioner
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rather than a concentrated whole herbal extract form or
concentrated isolated constituent of the plant, 2) the
dose is assumed to be at therapeutic levels, suitable for
oral administration, versus excessive consumption of the
herbal medicine or an alternate route of administration.
If an herbal medicinal product included several herbs,
each herbal was assessed individually and classified.
Statistical analysis
Factors associated with the use of contraindicated herbal
medicines in pregnancy (dichotomous variable: contrain-
dicated herbal medicine user versus non-contraindicated
herbal medicine user) were explored via the Generalized
Estimating Equations (GEE) [25]. The GEE method is
often used to analyze correlated response data such as
multiple observations over time for the same individual
or clustered data where observations are grouped based
on sharing some common characteristic. The use of the
GEE in the current study permitted the results to ac-
count for any clustering on region of residency. Data are
presented as adjusted odds ratios (aOR) with 95 % confi-
dence intervals (CI). A two-tailed p-value of <0.05 was
considered statistically significant. The multivariate GEE
model was developed by first selecting candidate variables
whose results, in a univariate model, had a p-value < 0.15.
Variables with a p-value >0.05, no effect, or those having
less than a 20 % impact on the beta coefficients of the
retained variables were not included in the multivariate
model. The final multivariate model included statistically
significant independent variables (i.e. employment status,
education level, folic acid use during pregnancy, alcohol
use during pregnancy, and recommendation source) and
potential confounders (i.e. age as a continuous variable).
All statistical analyses were performed by using the Statis-
tical Package for the Social Sciences (SPSS) version 20.0
(IBM® SPSS® Statistics).
Results
Of the 9615 women who indicated their willingness to
participate in the study, 9483 (98.6 %) accepted and com-
pleted the questionnaire. After exclusion of isolated re-
sponses from ineligible countries (n = 4), as well as from
the Central (n = 20) and South (n = 346) American re-
gions, we reached a final study population of 9113 women
from five different regions and 18 countries. The sam-
ple mostly included women from Western (n = 3201),
Northern (n = 2820) or Eastern Europe (n = 2342), followed
by North America (n = 533) and Australia (n = 217). A de-
tailed participant flow chart was previously published [13].
The sample was representative of the birthing populations
in each participating country with respect to age, parity and
smoking habits [13]. However, our sample comprised a
greater number of women with high educational levels ver-
sus the general birthing population in each country. In
total, 29.3 % of the women (n = 2673) reported the use
of herbal medicines in pregnancy. We were able to
identify the specific herbal medicines used by 2379
women (89.0 %). Specific herbals could not be identi-
fied for the remaining 294 women (11.0 %), as these
women either provided a general response, such as “herbal
teas,” the manufacturer’s name rather than that of the
herbal medicine or replied that she could not remember.
These cases were therefore not included in the safety
evaluation.
There were 126 different herbal medicines used in preg-
nancy, and which could be evaluated according to their
safety in pregnancy. Twenty-seven out of 126 herbal medi-
cines were classified as contraindicated in pregnancy and
these are detailed in Additional file 1: Table S1a. Of the
analzed population of 2379 women, contraindicated herbal
medicines were used by 476 women (20.0 %) (Table 1).
The most frequently used contraindicated herbal medi-
cines were Vaccínium vítis-idaéa (cowberry) (29.8 %),
Levisticum officinale (lovage) (19.7 %), and Leonurus
cardiaca (motherwort) (16.6 %). Twenty-eight herbal
medicines were classified as safe for use in pregnancy
(Additional file 1: Table S1b). These herbal medicines were
used by the largest number of women (n = 1128, 47.4 %)
(Table 1). The most frequently used herbal medicines clas-
sified as safe were Zingiber officinale (ginger) (56.7 %),
Vaccinium oxycoccus/macrocarpon (cranberry) (55.0 %),
and Mentha x piperita (peppermint) (15.9 %)
The greatest number of herbal medicines were classified
as requiring caution in pregnancy (Additional file 1: Table
S1d). Sixty herbal medicines were used by 751 women
(31.6 %) (Table 1). Thirty-six (36/60, 60 %) of the herbal
medicines in this group had limited evidence of the safety
for use in pregnancy whereas the remaining 24 (40 %) had
some evidence of potentially harmful effects in pregnancy.
The most frequently used herbal medicines classified as
requiring caution in pregnancy were Valeriana officinalis
(valerian) (n = 388), Rubus idaeus (raspberry) (n = 301)
and Rosa canina (dog-rose) (n = 148).
There were 11 herbal medicines for which no informa-
tion on the safety in pregnancy could be found. These
herbal medicines were used by only 24 women, represent-
ing a small portion of herbal medicine use (1.1 %) (Table 1).
These herbs were Algae (algae), Aronia melanocarpa (black
chokeberry), Bidens tripartita (water agrimony), Calluna
vulgaris (heather), Citricidal sp. (grapefruit extract), Cucur-
bita pepo (cucurbit/squash), Fagopyrum esculentum
(buckwheat), Hippophae rhamnoides (sea buckthorn),
Olea europaea (olive), Potentilla reptans (potentilla),
and Rhodiola rosea (rhodiola).
There was an important difference between regions in
terms of safety of herbal medicines used (Fig. 1). North
America had the highest number of herbal medicines that
were classified as contraindicated in pregnancy (19.5 %);
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however, a small number of women (10.9 %) used these
herbal medicines. Among the contraindicated herbs
used by women in North America were Cannabis spp.
(marijuana) and Carica papaya (papaya).
Eastern Europe had the highest number of users of both
contraindicated herbal medicines (33.1 %) and “use with
caution in pregnancy” category (36 %). Among the contra-
indicated herbs used by women in Eastern Europe were
Vaccínium vítis-idaéa (cowberry), Levisticum officinale
(lovage) and Leonurus cardiaca (motherwort). Women in
this region exclusively used these herbal medicines.
Risk factors
Several important maternal factors were found to be as-
sociated with the use of contraindicated herbal medi-
cines in pregnancy; namely, working in the home, having
a university education, not using folic acid and consum-
ing alcohol. Despite our initial hypothesis that women
would inadvertently use contraindicated herbal medi-
cines based on either their own initiative or upon the
recommendation from family or friends, we found that
the recommendation to take a contraindicated herbal
medicine was three times more likely to be from a HCP
than an informal source. Factors associated with the use
of contraindicated herbal medicines in pregnancy are
summarized in Table 2.
Discussion
To our knowledge, this is the first study to explore the
safety of herbal medicines use in pregnancy across several
regions of the world. Several of the findings are of clinical
importance. Firstly, it is reassuring that the majority of
women reported using herbal medicines that were consid-
ered safe for use during pregnancy. On the other hand, it is
of concern that there still are a substantial number of
women using potentially harmful herbal medicines during
pregnancy. This is especially worrisome since health care
professionals more frequently recommended use of these
herbal medicines than other sources. Most of the contrain-
dications were because of evidence of being emmenagogues
and/or uterine stimulants (Caulophyllum thalictroides (blue
cohosh), Cimicifuga racemosa (black cohosh), Capsella
bursa-pastoris (shepherd’s purse)) which could result in
negative pregnancy outcomes (Table 1). Secondly, it is
clear that there are regional differences in herbal tradi-
tions. For example, a substantial proportion of women
from Eastern Europe exclusively used three herbal medi-
cines. While, the largest group of contraindicated herbal
Fig. 1 Percentage of herbal medicines used and the number of women who used these herbal medicines by safety classification, overall and by region
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medicine users were those from North America. Clinicians
and health care personnel in care of pregnant women in
countries with high use of contraindicated herbal medi-
cines in pregnancy should evaluate these findings. Clearly,
this represents an opportunity for further detailed investi-
gations with respect to both maternal and neonatal out-
comes. Thirdly, this study highlights the urgent need for
more data on safety and efficacy of herbal medicine during
pregnancy. A recent systematic review on the use of herbal
medicine in pregnancy could only identify 14 RCTs evalu-
ating five different herbal medicines [26]. The most stud-
ied herbal medicine is Zingiber officinale (ginger) with 10
individual studies. The remaining other herbal medicines
were Vaccinium oxycoccus/macrocarpon (cranberry), Hy-
pericum perforatum (St. John’s wort), Rubus idaeus (rasp-
berry) and Allium sativum (garlic) with one study each.
This lack of depth in evidence represents a challenge to
health care personnel caring for pregnant women.
In several instances, where there was no information on
the impact of the herbal medicine in human pregnancy,
animal studies were used to determine the classification
(see references in Additional file 1: Table S1a-d). However,
results from animal studies may not be directly extrapo-
lated to humans [20, 27, 28].
Challenges classifying herbal safety in pregnancy
This study also presents a practical illustration of how
challenging it is to classify safety of herbal medicine. The
sources we used gave, at times, different classification rec-
ommendations representing different regional traditions
or points of view. For example, of the herbal medicines
that were included in this study and evaluated by the
European Medicines Agency, only two herbal medicines
have the status of “may be considered for use” in preg-
nancy Psyllii semen/Plantago ovata (psyllium) [29] and
Salix alba (white willow) [30]. This legislative approach is
not reflected in the classifications presented here. Further,
traditionally, herbal medicines are often used in combin-
ation. However, existing literature sources do not classify
combinations of herbal medicines. Although we classified
Table 2 Factors associated with the use of contraindicated herbal medicines in pregnancy
No use of CI herbals Use of CI herbals Total Adjusted Odds Ratio (95 % CI)
N % N %
Age (continuous) 0.95 (0.90–1.01)
Employment status
Student 183 77.2 54 22.8 237 1.05 (0.87–1.25)
Housewife 163 79.9 41 20.1 204 1.45 (1.18–1.79)
HCP 209 80.7 50 19.3 259 1.07 (0.55–2.08)
Job seeker 68 82.9 14 17.1 82 1.00 (0.39–2.58)
None 81 79.4 21 20.6 102 1.02 (0.67–1.54)
Employed other sector 1197 80.2 296 19.8 1493 Reference
Education level
Primary 66 85.7 11 14.3 77 0.90 (0.43–1.85)
High School 441 83.8 85 16.2 526 Reference
University 1166 77.8 332 22.2 1498 1.97 (1.60–2.44)
Other 230 82.7 48 17.3 278 1.18 (1.00–1.39)
Folic acid use before and/or during pregnancy
Yes 1819 80.1 453 19.9 2272 Reference
No 84 78.5 23 21.5 107 1.44 (1.14–1.82)
Alcohol use after awareness of pregnancy
Yes 393 76.3 122 23.7 515 1.48 (1.20–1.80)
Can’t remember 20 71.4 8 28.6 28 1.48 (0.82–2.66)
No 1490 81.2 345 18.8 1835 Reference
Recommendation source
Informal (family, internet, etc) 780 89.2 94 10.8 874 Reference
Other 24 88.8 3 11.2 27 0.97 (0.29–3.26)
Health care personnel 362 73.7 129 26.3 491 3.02 (2.65–3.57)
Both Informal and health care personnel 435 76.2 136 24.8 571 2.56 (2.35–2.78)
"Bold data" highlights statistically significant data
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women using several herbals according to the most harm-
ful herbal used, we did not considered potential synergistic
effects or interaction between the herbals. With the in-
creasing prevalence of the use of herbal medicines and
their availability as non-prescription products designed for
self-selection there is a need for high quality information
on the safety in pregnancy of both single and combination
herbal medicines.
Discussion on specific herbals
The herbal medicine, Rubus idaeus (raspberry) is classified
as “use with caution” in pregnancy despite its long history
of traditional and widespread use by women in pregnancy
[31]. This classification was done, in part, to highlight the
high need for additional research on this herbal medicine
and its use in pregnancy. The evidence for its use is
currently limited to one RCT and an observational
study [26, 31]. Finding from these studies suggest that
the intake of raspberry did not have negative fetal or
pregnancy outcomes; however, its use did not demon-
strate any benefits [31].
With respect to the use of Vaccinium oxycoccus/macro-
carpon (cranberry), its’ use was classified as “safe for use”
in pregnancy. Cranberry is another frequently used herbal
medicine for both urinary tract infection (UTI) prophylaxis
and treatment [13, 26]. There is evidence from studies with
non-pregnant patients that suggests that Cranberry can be
helpful for reducing UTI recurrence [26, 32, 33]; however,
the evidence to support its effectiveness in UTI treatment
in pregnancy is weak [34]. No negative fetal or pregnancy
outcomes were identified in a large retrospective cohort
study involving 68522 women, of whom 919 used cran-
berry in pregnancy [35]. However, as UTIs may have nega-
tive effects on pregnancy outcomes [36], it is essential that
antibiotics are used to treat UTIs and that herbal medi-
cines are not used as alternative to conventional prescribed
medication for UTIs in pregnancy.
The herbal medicines Leonarus cardiaca (motherwort)
and Levisticum officinale (lovage) are two herbal medi-
cines that were classified as contraindicated for use in
pregnancy. The rationale for this classification is based
on the emmenagogue action of these herbal medicines
[21, 37]. An emmenagogue is an herbal medicine that
stimulates menstrual flow and activity [38]. Sources refer
also to motherwort as a nervine (having a potentially
beneficial effect on the nervous system [38]) and as a car-
diotonic (having observable beneficial action on the heart
and blood vessels [38]), while lovage also acts as a bitter
(having an impact on the digestive system [38]) which can
help to address indigestion and anti-spasmodic actions
[38]. Both of these herbal medicines were used by women
in Russia only and used by 11 % of herbal users in Russia.
The scope of the study did not include the collection of
fetal and pregnancy outcomes, dosage, nor frequency of
use data, so whether the classification of both of these
herbal medicines as contraindicated in pregnancy is ap-
propriate requires further study.
Strengths and Limitations
This was the first study that uniformly collected infor-
mation regarding the use of herbal medicines in preg-
nancy and attempted to classify the herbal medicines
used, bringing together perspectives from several sources
and countries into the classification. The use of a web-
based recruitment strategy enabled us to reach a wide
segment of the birthing population. Further, we sought
to determine the maternal risk factors for the use of con-
traindicated herbal medicines, highlighting the need for
additional education and research for healthcare practi-
tioners with respect to herbal safety in pregnancy.
There are some limitations to bear in mind regarding
this study. Firstly, women were invited to participate via
banners posted on pregnancy-related websites. The study
design implied no probability sampling of the target popu-
lation; respondents were those women who happened to
have internet access, visited the website(s) where the invi-
tation was posted, and decided to participate in the survey.
Hence, the possibility of a self-selection bias cannot be
ruled out. On the other hand, the anonymous web-based
approach may be especially appropriate for childbearing-
age women residing in countries with high internet pene-
tration rates, as it was in this study (range 60 to 97 %) [39].
Since women have been shown to use the internet in a very
high extent during pregnancy to search for pregnancy-
related information [40, 41] this population is probably a
suitable target group in e-epidemiology.
Recent epidemiological studies indicate the validity of
web-based recruitment methods [42, 43]. We previously
assessed the representativeness of the study participants
to the general birthing populations in each study and
found that the women in the study had higher education
and were slightly more often primiparous than the gen-
eral birthing populations in the various countries [44]).
Moreover, since an online questionnaire was used, it is
not possible to calculate a conventional response rate.
However, of the women who indicated their willingness
to participate, 98.6 % completed the questionnaire.
As in all studies based on self-reported data, the accur-
acy of our data depends on the accuracy of maternal
reporting. Our estimates are likely to be an underestima-
tion of the true prevalence of herbal medicine use in preg-
nancy as we were dependent upon women to recall which
herbal medicines were taken and herbal names were not
specifically queried in the questionnaire. We did not cap-
ture the plant part, type of extract, dose, dose form or, dur-
ation of the use of the herbal medicine in pregnancy.
Capturing this data would have permitted more extensive
evaluations of contraindication or caution for use. Our
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results should be interpreted with these strengths and lim-
itations in mind.
Conclusion
Based on the current literature the majority of women in
this study used an herbal medicine that was classified as
safe for use in pregnancy. Women who reported taking a
contraindicated herb were more likely to have been rec-
ommended this use by an HCP rather than informal
source(s), indicating an urgent need for more education
among HCPs. The paucity of human studies on herbal
medicines safety in pregnancy stands in stark contrast to
the widespread use of these products among pregnant
women.
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